Denis Grizelj

Denis Grizelj is the CEO and Co-Founder of MD Labs, a leading innovator in pharmacogenetics and personalized medicine. With a solid background in business management, Denis plays a key role in overseeing the operations at Rxight, particularly in the areas of billing and insurance authorizations. His deep commitment to improving healthcare is evident in his passionate advocacy for Rxight pharmacogenetic testing, a service that empowers individuals to better manage their medications and avoid dangerous adverse drug reactions (ADRs).

Denis’s personal connection to Rxight pharmacogenetic testing has been life-changing. Having seen the profound impact it has had on his own family members by optimizing their medication management and reducing the risk of ADRs, Denis remains dedicated to advancing the reach and capabilities of Rxight in the healthcare space.

A significant milestone in Denis's journey was in 2016, when he, along with Matthew Rutledge and other key MD Labs team members, was invited to the White House to speak at the Office of Science and Technology Policy about the transformative role of pharmacogenetics in the Precision Medicine Initiative. This pivotal moment highlighted the importance of Rxight and pharmacogenetics in shaping the future of personalized healthcare.

As the CEO of MD Labs, Denis is excited about the future of pharmacogenetics and how Rxight is helping healthcare providers make more informed decisions regarding patient medications and dosages. With the increasing recognition of pharmacogenetic testing's value in improving patient outcomes, Denis remains committed to ensuring Rxight is the leading pharmacogenetic test on the market.

Denis keeps up-to-date with the latest trends and advancements in the pharmacogenetics industry to continue optimizing Rxight. By staying at the forefront of the industry, MD Labs is able to offer the most innovative and accurate pharmacogenetic test on the market, ultimately enhancing the medication management and overall health outcomes for individuals.

For more insights into pharmacogenetic testing and personalized medicine, connect with Denis Grizelj on LinkedIn.